Arginine hydrochloride

Phase 3Small molecule

TThe First Affiliated Hospital of Zhengzhou University

Arginine hydrochloride is one of 73 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic KetoacidosisActive, not recruiting

Acute Chest SyndromeActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

COVID-19Active, not recruiting

Diabetic KetoacidosisPhase 1/Phase 2

Active, not recruiting

Acute Chest SyndromePhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Arginine hydrochloride

TThe First Affiliated Hospital of Zhengzhou University

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Biaxin

AbbVie

Preclinical

2 4

Singulair

AstraZeneca

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Glucocorticoid

AbbVie

Preclinical

1 7

Nadroparin

GSK

Preclinical

1 8

Orap

Teva

Preclinical

1 9

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 10

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

COVID-19

NCT05855330

Q4 2027

Phase 1/2Recruiting

Diabetic Ketoacidosis

NCT07167693

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Treatment of Intermediate-stage Hepatocellular Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03274427·300 enrolled

Treatment of Advanced Hepatocellular Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03278444·300 enrolled

Novel Treatment of Advanced Hepatocellular Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03950518·300 enrolled

Diabetic Ketoacidosis1 trial

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Recruiting·DDavid K Carroll·Phase 1/2·NCT07167693·60 enrolled

COVID-191 trial

Arginine Replacement Therapy in COVID-19

Recruiting·EEmory University·Phase 2·NCT05855330·21 enrolled

Type 1 Diabetic1 trial

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

Completed·YYale University··NCT00958997·16 enrolled

Acute Chest Syndrome1 trial

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

Completed·UUCSF Benioff Children's Hospital Oakland·Phase 2·NCT00029731·30 enrolled

1 more indication

Prevention1 trial

Prevention of Cancer Development and Progression

Unknown status·ZZujiang YU·Phase 3·NCT03940053·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Arginine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arginine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arginine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Zhengzhou University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe First Affiliated Hospital of Zhengzhou University

Arginine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Diabetic Ketoacidosis1 trial

COVID-191 trial

Type 1 Diabetic1 trial

Acute Chest Syndrome1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News